Monday, June 17, 2019 12:14:14 PM
Tier 1 preferred generic
Tier 2 generic
Tier 3 preferred brand
That's Silverscrips I assume? Explains the pricing and copay questions I had if yes - and to be honest, I thought I hadn't seen tiers like that before - but I'll be damned, went back and looked up my old Aetna and current Humana formularies, and they use the same tier definitions - where I came up with "T2 is preferred name brand" I have no idea, but clearly I've been using the wrong tier that V should be on for quite some time - also makes me wonder why JT said "over 90% of adult lives on Medicare Part D covered by insurance predominantly tier 2" when V appears to be ineligible for T2 on a Part D plan as it's not generic.
Ok, had to look this up - Medicare.gov says T2 "can be" preferred brand name, but we now know three large Part D provides, Aetna, Humana, and Silverscrips, do not use these tier definitions:
https://www.medicare.gov/drug-coverage-part-d/what-drug-plans-cover
To lower costs, many plans place drugs into different “Tiers” on their formularies. Each plan can divide its tiers in different ways. Each tier costs a different amount. Generally, a drug in a lower tier will cost you less than a drug in a higher tier.
Here's an example of a plan's tiers (your plan’s tiers may be different):
Tier 1—lowest Copayment : most generic prescription drugs
Tier 2—medium copayment: preferred, brand-name prescription drugs
Tier 3—higher copayment: non-preferred, brand-name prescription drugs
Specialty tier—highest copayment: very high cost prescription drugs
In some cases, if your drug is in a higher (more expensive) tier and your prescriber thinks you need that drug instead of a similar drug on a lower tier, you can file an Exception and ask your plan for a lower copayment.
Remember, this is only an example—your plan's tiers may be different.
Note: Medicare.com, which is not government sponsored, also uses the same tier definitions as Medicare.gov - no wonder I was confused. And sheesh, BCBS of Michigan uses SIX tiers!
https://www.bcbsm.com/medicare/help/understanding-plans/pharmacy-prescription-drugs/tiers.html
Tier 6 Select care. These are generic drugs used to treat diabetes and high cholesterol For most plans, you'll pay $0-$5 for drugs in this tier..
So JT's "T2" statement is even more effed up now from where I sit - and it's not an issue that has sparked arguments here, what the copay is if covered and whether it's affordable, it's the tier he claims V is on for 90% of Part D plans - I'd be willing to bet the majority of plans use the tier defs you provided, meaning V is T3 (or T4) if on formulary.
Had to look *that* up too - UnitedHealth, Humana, and CVS Health cover 55% of Part D enrollees in 2018:
https://www.kff.org/medicare/issue-brief/medicare-part-d-in-2018-the-latest-on-enrollment-premiums-and-cost-sharing/
All three of those Part D plans (Silverscrips is a subsidiary of CVS Health) use T3 as preferred brand name, so this debate is over - JT's statement is plain wrong, end of story.
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
